Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682224 · ClinicalTrials.gov registry record · Phase 3
Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
A Phase 3 study, sponsored by Southern Illinois University.
- Completed
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
NCT03682224 is a Phase 3 study that has completed, run by Southern Illinois University. The registered enrollment target is 57 participants.
The verdict
NCT03682224, a Phase 3 study, has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to assess pain management after elective thoracoscopic lobectomy. The study will compare two local anesthetics that are given intra-operatively during lobectomy to see which one helps in better pain control and to see which one helps decrease the need for opioid medications. Participants will receive either Marcaine (Bupivacaine-epinephrine 0.25%, 1:200,000) or Exparel (Bupivacaine liposomal (1.3%)) and the drug will be chosen in a random fashion. Participants will be followed during the hospital stay and for one year thereafter. An visual Scale will be administered to measure pain, and opioid drug use will be measured by calculating morphine equivalent dose on each day post surgery until discharge and thereafter on 30 day, 6 month and 12 month follow-up visits. Participants will be monitored for any drug related toxicity and other co-morbid conditions for a period on one year post surgery. Overall cost for the surgery and during in hospital stay post surgery will be collected and compared between the two treatment arms.
Interventions
- DRUG Liposomal Bupivacaine
- DRUG Bupivacaine-Epinephrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2022-09-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03682224
The ClinicalTrials.gov registry entry for NCT03682224 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern Illinois University, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivacaine is the first listed.
NCT03682224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03682224 about?
NCT03682224 is a clinical study titled "Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients". The purpose of this study is to assess pain management after elective thoracoscopic lobectomy. The study will compare two local anesthetics that are given intra-operatively during lobectomy to see which one helps in better pain control and to see which one helps decrease the need for opioid medicati...
What is the current status of trial NCT03682224?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2018-07-05. Estimated completion is 2022-09-03.
What interventions are being tested in trial NCT03682224?
The interventions under investigation include: Liposomal Bupivacaine (DRUG), Bupivacaine-Epinephrine (DRUG).
Who is sponsoring clinical trial NCT03682224?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.